Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
- PMID: 34012067
- PMCID: PMC8354850
- DOI: 10.1038/s41436-021-01170-5
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
Abstract
Purpose: By incorporating major developments in genetics, ophthalmology, dermatology, and neuroimaging, to revise the diagnostic criteria for neurofibromatosis type 1 (NF1) and to establish diagnostic criteria for Legius syndrome (LGSS).
Methods: We used a multistep process, beginning with a Delphi method involving global experts and subsequently involving non-NF experts, patients, and foundations/patient advocacy groups.
Results: We reached consensus on the minimal clinical and genetic criteria for diagnosing and differentiating NF1 and LGSS, which have phenotypic overlap in young patients with pigmentary findings. Criteria for the mosaic forms of these conditions are also recommended.
Conclusion: The revised criteria for NF1 incorporate new clinical features and genetic testing, whereas the criteria for LGSS were created to differentiate the two conditions. It is likely that continued refinement of these new criteria will be necessary as investigators (1) study the diagnostic properties of the revised criteria, (2) reconsider criteria not included in this process, and (3) identify new clinical and other features of these conditions. For this reason, we propose an initiative to update periodically the diagnostic criteria for NF1 and LGSS.
© 2021. The Author(s).
Conflict of interest statement
D.V.-B. is a scientific advisor for AstraZeneca Pharmaceuticals, LP, and receives grant support for the Department of Defense and SpringWorks Therapeutics. J.B. and M.J.F. are members of the Children’s Tumor Foundation Medical Advisory Committee. D.G.E., E.L., V.-F.M., S.P. are members of the Children’s Tumor Foundation Clinical Care Advisory Board-Europe. R.F. is a member of the Children’s Tumor Foundation Clinical Care Advisory Board-Europe and is a medical advisor for AstraZeneca. J.M.F. is a member of the Children’s Tumor Foundation Clinical Care Advisory Board. B.R.K. is a member of the Children’s Tumor Foundation Medical Advisory Committee (Chair) and is on the medical advisory boards of Genome Medicine and Infixion Bioscience. L.M. is director of the Medical Genomics Laboratory at University of Alabama, Birmingham, which specializes in genetic testing for all forms of the neurofibromatoses. P.P. is employed by the Children’s Tumor Foundation. S.R.P. is a member of the Children’s Tumor Foundation Clinical Care Advisory Board (Chair, US) and Europe, and is co-founder of NFlection Therapeutics; is consultant for AstraZeneca and SonalaSense. E.S. is a member of the Children’s Tumor Foundation Clinical Care Advisory Board and receives Department of Defense funding as a site for NF Clinical Trials Consortium. N.J.U. is a member of the Children’s Tumor Foundation Clinical Care Advisory Board and serves on the board of NF Northeast. D.V. is member of the Children’s Tumor Foundation and Medical Advisory Committee, is a member of the AstraZeneca speakers bureau, and is on Sanofi-Genzyme–MPS Board of Advisors. P.W. is a member of the Children’s Tumor Foundation Clinical Care Advisory Board–Europe (Chair). K.Y. is a member of the Children’s Tumor Foundation Clinical Care Advisory Board; received a consultant fee from AstraZeneca Pharmaceuticals; is on the Scientific Advisory Board for Infixion Bioscience; and is a member of the Programmatic Review Committee for the Department of Defense, Congressionally Directed Medical Research Program, NF Research Program. The other authors declare no competing interests.
Similar articles
-
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.Genet Med. 2022 Sep;24(9):1967-1977. doi: 10.1016/j.gim.2022.05.007. Epub 2022 Jun 9. Genet Med. 2022. PMID: 35674741
-
Neurofibromatosis type 1: A comparison of the 1997 NIH and the 2021 revised diagnostic criteria in 75 children and adolescents.Genet Med. 2022 Sep;24(9):1978-1985. doi: 10.1016/j.gim.2022.05.013. Epub 2022 Jun 17. Genet Med. 2022. PMID: 35713653
-
Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature.Pediatr Neurol. 2016 Jul;60:24-29.e1. doi: 10.1016/j.pediatrneurol.2016.03.003. Epub 2016 Mar 19. Pediatr Neurol. 2016. PMID: 27212418 Review.
-
Evaluation of the impact of the 2021 revised Neurofibromatosis type 1 diagnostic criteria on time to diagnosis.Am J Med Genet A. 2022 Sep;188(9):2584-2589. doi: 10.1002/ajmg.a.62890. Epub 2022 Jul 2. Am J Med Genet A. 2022. PMID: 35779212
-
Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants.Hum Genet. 2022 Feb;141(2):177-191. doi: 10.1007/s00439-021-02410-z. Epub 2021 Dec 20. Hum Genet. 2022. PMID: 34928431 Free PMC article. Review.
Cited by
-
Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.J Patient Rep Outcomes. 2024 May 29;8(1):52. doi: 10.1186/s41687-024-00732-w. J Patient Rep Outcomes. 2024. PMID: 38811427 Free PMC article.
-
[Neurofibromatosis type 1 associated with pheochromocytoma: a case report with a brief review of the literature].Probl Endokrinol (Mosk). 2023 Sep 11;70(2):53-64. doi: 10.14341/probl13345. Probl Endokrinol (Mosk). 2023. PMID: 38796761 Free PMC article. Review. Russian.
-
Chronic kidney disease with malignant peripheral nerve sheath tumor of the ureter: a case report.Front Oncol. 2024 May 2;14:1368996. doi: 10.3389/fonc.2024.1368996. eCollection 2024. Front Oncol. 2024. PMID: 38756660 Free PMC article.
-
NF1 with 47,XYY mosaicism diagnosed by mandibular neurofibromas.Hum Genome Var. 2024 May 16;11(1):22. doi: 10.1038/s41439-024-00279-8. Hum Genome Var. 2024. PMID: 38755192 Free PMC article.
-
Cardiac screening in pediatric patients with neurofibromatosis type 1: similarities with Noonan syndrome?Int J Cardiovasc Imaging. 2024 Jul;40(7):1475-1482. doi: 10.1007/s10554-024-03125-8. Epub 2024 May 13. Int J Cardiovasc Imaging. 2024. PMID: 38739321
References
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous